Migraine
Neurology· 10 reviewed drugs· 8640 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for Migraine include drugs for both prophylaxis and acute treatment. For prophylaxis, Ajovy is indicated for adults with at least 4 migraine days per month, showing a reduction from baseline for primary endpoints with fremanezumab monthly dosing (episodic migraine) of 3-5. Vyepti, also for prophylaxis in adults with at least 4 migraine days per month, demonstrated a mean change from baseline in monthly migraine days of -4.29. EMGALITY, for prophylaxis of migraine headache in adults, showed an overall LS mean reduction from baseline in monthly migraine headache days of -4.8. Aimovig, for prophylaxis in adults with at least 4 migraine days per month, had a difference in LSM for MMD vs placebo of -2.46.
For acute treatment, Atogepant is indicated for migraine with or without aura in adults, with pain freedom at 2 hours post-dose reported as 24.3%. Lasmiditan, for acute treatment of the headache phase of migraine attacks, showed pain freedom at 2 hours post-dose of 38.8. Rimegepant, for acute treatment of migraine with or without aura, reported pain freedom at 2 hours of 19.6. Ubrelvy, for acute treatment of migraine with or without aura, showed pain freedom at 2 hours (ubrogepant 50 mg) of 19.2 %. Nurtec-ODT, for acute treatment of migraine with or without aura, reported pain freedom at 2 hours (rimegepant vs placebo) of 5-10. It is important to note that different drugs were studied in different trials, so figures are not head-to-head comparisons.
The drugs — one cited result each
| Ajovy Teva Pharmaceutical Industries Limited | Reduction from baseline for primary endpoints with fremanezumab monthly dosing (episodic migraine): 3-5 Teva Pharmaceutical Industries Limited — Ajovy FDA Review (B, p.155 |
| Vyepti H. Lundbeck A/S | Mean change from baseline in monthly migraine days: -4.29 H. Lundbeck A/S — Vyepti FDA Review (BLA761119, ORIG 1, 2020, p.50 |
| Atogepant AbbVie Inc. | Pain freedom at 2 hours post-dose: 24.3% AbbVie Inc. — Aquipta EMA EPAR variation assessment report, p.52 |
| EMGALITY Eli Lilly and Company | overall LS mean reduction from baseline in monthly migraine headache days: -4.8 Eli Lilly and Company — Emgality FDA Review (BLA761063, ORIG, p.267 |
| lasmiditan Eli Lilly and Company | Pain freedom at 2 hours post-dose: 38.8 Eli Lilly and Company — Rayvow EMA EPAR public assessment re, p.87 |
| rimegepant Pfizer Inc. | Pain freedom at 2 hours: 19.6 Vydura EMA EPAR public assessment report (EMEA, p.78 |
| Aquipta AbbVie Inc. | LSMD (atogepant 60 mg QD vs. placebo) for monthly migraine days: -1.66 AbbVie Inc. — Aquipta EMA EPAR public assessment report (EME, p.81 |
| Ubrelvy AbbVie Inc. | Pain freedom at 2 hours (ubrogepant 50 mg): 19.2 % AbbVie Inc. — Ubrelvy FDA Review, p.39 |
| Aimovig Novartis AG | Difference in LSM for MMD vs placebo: -2.46 Novartis AG — Aimovig EMA EPAR public assessment report (EME, p.55 |
| Nurtec-ODT Pfizer Inc. | Pain freedom at 2 hours (rimegepant vs placebo): 5-10 Pfizer Inc. — Nurtec FDA Review (NDA212728, ORIG 1, 2020), p.14 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Neurology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.